JP2022532790A5 - - Google Patents

Info

Publication number
JP2022532790A5
JP2022532790A5 JP2021568766A JP2021568766A JP2022532790A5 JP 2022532790 A5 JP2022532790 A5 JP 2022532790A5 JP 2021568766 A JP2021568766 A JP 2021568766A JP 2021568766 A JP2021568766 A JP 2021568766A JP 2022532790 A5 JP2022532790 A5 JP 2022532790A5
Authority
JP
Japan
Prior art keywords
ray
powder
peaks
compound according
diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021568766A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022532790A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/033832 external-priority patent/WO2020236948A1/en
Publication of JP2022532790A publication Critical patent/JP2022532790A/ja
Publication of JP2022532790A5 publication Critical patent/JP2022532790A5/ja
Priority to JP2025080319A priority Critical patent/JP2025131597A/ja
Pending legal-status Critical Current

Links

JP2021568766A 2019-05-21 2020-05-20 固体形態 Pending JP2022532790A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025080319A JP2025131597A (ja) 2019-05-21 2025-05-13 固体形態

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962851049P 2019-05-21 2019-05-21
US62/851,049 2019-05-21
PCT/US2020/033832 WO2020236948A1 (en) 2019-05-21 2020-05-20 Solid state forms

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025080319A Division JP2025131597A (ja) 2019-05-21 2025-05-13 固体形態

Publications (2)

Publication Number Publication Date
JP2022532790A JP2022532790A (ja) 2022-07-19
JP2022532790A5 true JP2022532790A5 (cg-RX-API-DMAC10.html) 2023-05-24

Family

ID=71016701

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021568766A Pending JP2022532790A (ja) 2019-05-21 2020-05-20 固体形態
JP2025080319A Pending JP2025131597A (ja) 2019-05-21 2025-05-13 固体形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025080319A Pending JP2025131597A (ja) 2019-05-21 2025-05-13 固体形態

Country Status (10)

Country Link
US (1) US12252486B2 (cg-RX-API-DMAC10.html)
EP (1) EP3972972A1 (cg-RX-API-DMAC10.html)
JP (2) JP2022532790A (cg-RX-API-DMAC10.html)
AR (1) AR119741A1 (cg-RX-API-DMAC10.html)
AU (2) AU2020277398B2 (cg-RX-API-DMAC10.html)
CA (1) CA3140394A1 (cg-RX-API-DMAC10.html)
MX (2) MX2021014235A (cg-RX-API-DMAC10.html)
TW (1) TW202110836A (cg-RX-API-DMAC10.html)
UY (1) UY38711A (cg-RX-API-DMAC10.html)
WO (1) WO2020236948A1 (cg-RX-API-DMAC10.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20190338A (es) 2016-12-22 2019-09-09 Amgen Inc Inhibidores de kras g12c y métodos para su uso
UA127968C2 (uk) 2017-05-22 2024-02-28 Емджен Інк. Інгібітори g12c kras і способи їх застосування
US10640504B2 (en) 2017-09-08 2020-05-05 Amgen Inc. Inhibitors of KRAS G12C and methods of using the same
MX2020010836A (es) 2018-05-04 2021-01-08 Amgen Inc Inhibidores de kras g12c y métodos para su uso.
EP3788053B1 (en) 2018-05-04 2024-07-10 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
WO2019217691A1 (en) 2018-05-10 2019-11-14 Amgen Inc. Kras g12c inhibitors for the treatment of cancer
WO2019232419A1 (en) 2018-06-01 2019-12-05 Amgen Inc. Kras g12c inhibitors and methods of using the same
AU2019284472B2 (en) 2018-06-11 2024-05-30 Amgen Inc. KRAS G12C inhibitors for treating cancer
JP7369719B2 (ja) 2018-06-12 2023-10-26 アムジエン・インコーポレーテツド KRas G12C阻害剤及びそれを使用する方法
US12208099B2 (en) 2018-09-10 2025-01-28 Mirati Therapeutics, Inc. Combination therapies
SMT202500028T1 (it) 2018-09-10 2025-03-12 Mirati Therapeutics Inc Terapie combinate
AU2019338207B2 (en) 2018-09-10 2025-01-02 Mirati Therapeutics, Inc. Combination therapies
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
JP7516029B2 (ja) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Kras g12c阻害剤化合物の重要な中間体の改良合成法
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
JP7454572B2 (ja) 2018-11-19 2024-03-22 アムジエン・インコーポレーテツド Kras g12c阻害剤及びその使用方法
US12377101B2 (en) 2018-12-05 2025-08-05 Mirati Therapeutics, Inc. Combination therapies
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
EP3972973A1 (en) 2019-05-21 2022-03-30 Amgen Inc. Solid state forms
US12252486B2 (en) 2019-05-21 2025-03-18 Amgen Inc. Solid state forms
CN114615981B (zh) 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
CN114761012B (zh) 2019-09-24 2025-03-21 米拉蒂治疗股份有限公司 组合疗法
PH12022551513A1 (en) 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
US20230183235A1 (en) * 2020-05-20 2023-06-15 Teva Pharmaceuticals International Gmbh Solid state forms of amg-510 and process for preparation thereof
WO2021249563A1 (zh) * 2020-06-12 2021-12-16 苏州泽璟生物制药股份有限公司 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
US12655160B2 (en) 2020-08-04 2026-06-16 Mirati Therapeutics, Inc. KRAS G12D inhibitors
EP4210833A4 (en) 2020-09-11 2024-09-11 Mirati Therapeutics, Inc. CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR
EP4216951B1 (en) 2020-09-22 2026-04-01 Mirati Therapeutics, Inc. Kras g12d inhibitors
JP2023551006A (ja) * 2020-11-26 2023-12-06 上▲海▼翰森生物医▲薬▼科技有限公司 窒素含有複素環誘導体の塩、結晶、並びにその調製方法、及び使用
EP4262807A4 (en) 2020-12-15 2025-04-23 Mirati Therapeutics, Inc. Azachinazoline pan-KRAS inhibitors
WO2022133038A1 (en) 2020-12-16 2022-06-23 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
WO2022246069A1 (en) 2021-05-19 2022-11-24 Teva Pharmaceuticals International Gmbh Process for preparation of sotorasib and solid state form thereof
CN114605406B (zh) * 2021-09-18 2023-05-26 都创(上海)医药开发有限公司 Amg510化合物的晶型及其制备方法和用途
CN115368358A (zh) * 2022-09-01 2022-11-22 浙江九洲药业股份有限公司 一种Sotorasib新晶型及其制备方法与应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201312059D0 (en) 2013-07-05 2013-08-21 Univ Leuven Kath Novel GAK modulators
MX380928B (es) 2013-10-10 2025-03-12 Araxes Pharma Llc Inhibidores de kras g12c.
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Kras g12c之抑制劑
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
AU2016245864C1 (en) 2015-04-10 2021-09-09 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
ES2863873T3 (es) 2016-05-18 2021-10-11 Mirati Therapeutics Inc Inhibidores de KRAS G12C
CR20190338A (es) 2016-12-22 2019-09-09 Amgen Inc Inhibidores de kras g12c y métodos para su uso
UA127968C2 (uk) * 2017-05-22 2024-02-28 Емджен Інк. Інгібітори g12c kras і способи їх застосування
US10640504B2 (en) 2017-09-08 2020-05-05 Amgen Inc. Inhibitors of KRAS G12C and methods of using the same
MX2020010836A (es) 2018-05-04 2021-01-08 Amgen Inc Inhibidores de kras g12c y métodos para su uso.
JP7516029B2 (ja) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Kras g12c阻害剤化合物の重要な中間体の改良合成法
US12252486B2 (en) 2019-05-21 2025-03-18 Amgen Inc. Solid state forms
EP3972973A1 (en) 2019-05-21 2022-03-30 Amgen Inc. Solid state forms
EP4700030A3 (en) 2019-11-14 2026-03-18 Amgen, Inc. Improved synthesis of kras g12c inhibitor compound
CA3161156A1 (en) 2019-11-14 2021-05-20 Amgen Inc. Improved synthesis of kras g12c inhibitor compound

Similar Documents

Publication Publication Date Title
JP2022058395A5 (cg-RX-API-DMAC10.html)
HRP20221152T1 (hr) Spojevi korisni u inhibiranju cdk7
JP5852678B2 (ja) 抗腫瘍剤の効果増強剤
JP2021526132A5 (cg-RX-API-DMAC10.html)
JP6021805B2 (ja) 腫瘍治療剤
JP2021521194A5 (cg-RX-API-DMAC10.html)
JP2023522250A5 (cg-RX-API-DMAC10.html)
MX2025010774A (es) Formas en estado solido
CN119454706A (zh) 治疗kras相关癌症的方法
WO2006080327A1 (ja) α,α,α-トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤
CN101616671A (zh) 胰腺癌治疗用组合物
CN107296811B (zh) 一种用于治疗胃癌的喹啉衍生物
JP2018534289A5 (cg-RX-API-DMAC10.html)
JP2020536893A5 (cg-RX-API-DMAC10.html)
WO2018214925A1 (zh) 用于治疗结直肠癌的喹啉衍生物
ES2385850T3 (es) Potenciador de radioterapia
JP2022520361A (ja) 複素環式タンパク質キナーゼ阻害剤を含む製剤
JP7565118B2 (ja) (s,e)-4-(ジメチルアミノ)-n-(3-(4-(2-ヒドロキシ-1-フェネチルアミノ)-6-フェニルフロ[2,3-d]ピリミジン-5-イル)フェニル)ブタ-2-エナミド遊離塩基の結晶形
JP2024514995A5 (cg-RX-API-DMAC10.html)
TWI694067B (zh) 經氯苯取代之氮雜芳基化合物
WO2024209717A1 (ja) 腫瘍治療用医薬組成物
JP2018506562A5 (cg-RX-API-DMAC10.html)
JP2008501690A (ja) がんの治療方法
RU2017133093A (ru) Кристаллические формы соединения пирролопиридина
EP3492082B1 (en) Anticancer pharmaceutical composition